MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Please visit our MS learning channel on YouTube, which provides hundreds of MS videos presented by MS Experts across the USA, from many of our recorded education programs. Archived here: www.youtube.com/msviewsandnews -- Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram

Important Resources for the MS community are found on the left side of this blog.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Friday, October 15, 2010

Sanofi MS drug data show relapses cut by 31 pct

October 15, 2010
 MS drug candidate meets final phase clinical trial goals




* MS drug cuts annualised relapse rate by 31 pct vs placebo
* 7 mg and 14 mg doses of teriflunomide well tolerated
(Adds detail from statement)
By Caroline Jacobs
PARIS, Oct 15 (Reuters) - Sanofi-Aventis (SASY.PA), locked in a battle to buy U.S. biotech Genzyme (GENZ.O), said its multiple sclerosis candidate drug teriflunomide significantly cut relapses in patients who took the once-daily oral treatment.
The outcome of the final phase clinical trial showed that two different doses of the drug cut the annualised relapse rate of the chronic disease by 31 percent against placebo and that patients tolerated both doses well, the French drugmaker said on Friday.
Sanofi's two-year trial data follows those of Genzyme, a rare disease specialist, showing in five-year clinical results that its MS experimental drug alemtuzumab or Campath continued to show strong efficacy with no new or worsening side effects. [ID:nN13242220]
Sanofi's so-called TEMSO trial also demonstrated that the risk of progression in disability fell 30 percent in patients who were given 14 mg of teriflunomide and was down 24 percent for those on half the dose.
Teriflunomide had no major safety concerns, according to Sanofi, which cited diarrhea and nausea in patients on the higher dose as well as alanine transferase increases that were mainly mild.
The study involved 1,088 patients who were either on 7 mg or 14 mg doses of teriflunomide or on a placebo.
"We are very pleased with the successful results of the TEMSO study which are an important step forward in multiple sclerosis clinical research," Sanofi's head of research Marc Cluzel said in a statement.


***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

No comments: